These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19346961)

  • 21. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.
    Turetschek K; Preda A; Novikov V; Brasch RC; Weinmann HJ; Wunderbaldinger P; Roberts TP
    J Magn Reson Imaging; 2004 Jul; 20(1):138-44. PubMed ID: 15221819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contrast-enhanced CT of the liver and spleen: comparison of ionic and nonionic contrast agents.
    Nelson RC; Chezmar JL; Peterson JE; Bernardino ME
    AJR Am J Roentgenol; 1989 Nov; 153(5):973-6. PubMed ID: 2801447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison between IEEC, a new biodegradable particulate contrast medium, and iohexol in a tumor model of computed tomography imaging of the liver.
    Leander P; Golman K; Strande P; Klaveness J; Besjakov J; Fält K
    Invest Radiol; 1993 Jun; 28(6):513-9. PubMed ID: 8320069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contrast-enhanced microcomputed tomography using intraperitoneal contrast injection for the assessment of tumor-burden in liver metastasis models.
    Graham KC; Detombe SA; MacKenzie LT; Holdsworth DW; MacDonald IC; Chambers AF; Drangova M
    Invest Radiol; 2008 Jul; 43(7):488-95. PubMed ID: 18580331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
    Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
    Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
    Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
    Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic resonance imaging assays for dimethyl sulfoxide effect on cancer vasculature.
    Cyran CC; Sennino B; Chaopathomkul B; Fu Y; Rogut V; Shames DM; Wendland MF; McDonald DM; Brasch RC
    Invest Radiol; 2008 May; 43(5):298-305. PubMed ID: 18424950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
    Bäuerle T; Bartling S; Berger M; Schmitt-Gräff A; Hilbig H; Kauczor HU; Delorme S; Kiessling F
    Eur J Radiol; 2010 Feb; 73(2):280-7. PubMed ID: 19070445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats.
    Fournier LS; Novikov V; Lucidi V; Fu Y; Miller T; Floyd E; Shames DM; Brasch RC
    Radiology; 2007 Apr; 243(1):105-11. PubMed ID: 17329684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CT depiction of experimental liver tumors: contrast enhancement with hepatocyte-selective iodinated triglyceride versus conventional techniques.
    Lee FT; Chosy SG; Naidu SG; Goldfarb S; Weichert JP; Bakan DA; Kuhlman JE; Tambeaux RH; Sproat IA
    Radiology; 1997 May; 203(2):465-70. PubMed ID: 9114106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.
    Tai JH; Tessier J; Ryan AJ; Hoffman L; Chen X; Lee TY
    Neoplasia; 2010 Sep; 12(9):697-707. PubMed ID: 20824046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression.
    Kambadakone A; Yoon SS; Kim TM; Karl DL; Duda DG; DeLaney TF; Sahani DV
    AJR Am J Roentgenol; 2015 Jan; 204(1):W11-8. PubMed ID: 25539263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbits.
    Saati S; Agrawal RN; Louie S; Chader GJ; Humayun MS
    Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):457-66. PubMed ID: 19644699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.
    Bachelier R; Confavreux CB; Peyruchaud O; Croset M; Goehrig D; van der Pluijm G; Clézardin P
    Int J Cancer; 2014 Sep; 135(6):1319-29. PubMed ID: 24615579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-labeled liposomes for CT imaging of atherosclerotic plaques: in vitro investigation of an anti-ICAM antibody-labeled liposome containing iohexol for molecular imaging of atherosclerotic plaques via computed tomography.
    Danila D; Partha R; Elrod DB; Lackey M; Casscells SW; Conyers JL
    Tex Heart Inst J; 2009; 36(5):393-403. PubMed ID: 19876414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy.
    Ng CS; Charnsangavej C; Wei W; Yao JC
    AJR Am J Roentgenol; 2011 Mar; 196(3):569-76. PubMed ID: 21343498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
    Azad NS; Annunziata CM; Steinberg SM; Minasian L; Premkumar A; Chow C; Kotz HL; Kohn EC
    Cancer; 2008 Apr; 112(8):1726-32. PubMed ID: 18300236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.
    Lee SY; Kim DK; Cho JH; Koh JY; Yoon YH
    Arch Ophthalmol; 2008 Jul; 126(7):953-8. PubMed ID: 18625942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.